|
Post by castlerockchris on Jan 8, 2024 13:39:04 GMT -5
The latter. I am surprised Oppenheimer didn't result in more analyst coverage. We need a couple of big houses to add favorable coverage. It will probably come once something big happens and our stock consistently trades in the $7-10 range. The problem is I am no longer confident India or Peds announcement of approval will move the needle. Now if either of those happens and scripts move up quickly and consistently (+200 per month and and refills rise with it) then I think you will see some fireworks only after at least one quarterly conference call and realistically not until two. I just don't see Affrezza leading to explosive stock movement (+50 - 60%), other than the predictable immediate 30 - 50 cent bump followed by a slow retreat, until MNKD proves they can monetize the approval. Adding 300 - 400 scripts over two quarters and then returning to the slow slog upward in scripts isn't going to deliver a $8 share price, it might get us to $5. My gut says MNKD 101 is the next big needle mover, if/when it happens and within a couple of quarters of that we could see $7 - 8 if the company performs similar to what UTHR did with T-DPI.
|
|
|
Post by hellodolly on Jan 8, 2024 14:47:35 GMT -5
The latter. I am surprised Oppenheimer didn't result in more analyst coverage. We need a couple of big houses to add favorable coverage. It will probably come once something big happens and our stock consistently trades in the $7-10 range. The problem is I am no longer confident India or Peds announcement of approval will move the needle. Now if either of those happens and scripts move up quickly and consistently (+200 per month and and refills rise with it) then I think you will see some fireworks only after at least one quarterly conference call and realistically not until two. I just don't see Affrezza leading to explosive stock movement (+50 - 60%), other than the predictable immediate 30 - 50 cent bump followed by a slow retreat, until MNKD proves they can monetize the approval. Adding 300 - 400 scripts over two quarters and then returning to the slow slog upward in scripts isn't going to deliver a $8 share price, it might get us to $5. My gut says MNKD 101 is the next big needle mover, if/when it happens and within a couple of quarters of that we could see $7 - 8 if the company performs similar to what UTHR did with T-DPI. Of the recent addition of cash to the balance sheet coming from the Sagard deal, the restructuring of the sales force and the INDIA results imminently due what, if any amount of cash, do you think MNKD might use to co-commercialize/market Afrezza in INDIA with CIPLA? The timing of all of this is important and relevant beyind the talk about stock options and awards, compensation to the board.
|
|
|
Post by caesar on Jan 8, 2024 14:56:37 GMT -5
WedBush: We reiterate our OUTPERFORM rating and $10 twelve-month PT including lowering the Tyvaso DPI royalty to 9% from 10%
On Jan. 2, MannKind announced a royalty purchase agreement with Sagard Healthcare whereby MannKind sold a 1% royalty in net sales of Tyvaso DPI in exchange for up to $200M including $150M upfront and an additional milestone payment of up to $50M. Cash of $144.3M at the end of Q3:23 provides sufficient runway into the foreseeable future further strengthened by the upfront payment from the royalty purchase agreement. We see the deal as a strong indicator of Tyvaso DPI's blockbuster potential in both PAH and PH-ILD as well as confidence in its growth trajectory despite possible new entrants in the market like Merck's (MRK; not covered) sotatercept with its March 26, 2024 PDUFA and Liquidia's (LQDA; Argyrides; UP) DPI treprostinil, YUTREPIA. We maintain our view that Tyvaso DPI would maintain its strong foothold in the PAH and PH-ILD markets and continue along its growth trajectory given 1) MannKind's increased manufacturing capacity (~25K-35K in 2024 from ~7K-10K in 2023) providing United with the capability to sufficiently fulfill growing patient demand especially in PHILD (~30K U.S. patients) where Tyvaso DPI is the only approved product other than Tyvaso, 2) YUTREPIA's lack of meaningful differentiation from Tyvaso DPI according to our prior conversations with experts (see notes HERE, HERE and HERE), 3) Tyvaso DPI's ~1.6yr year advantage over YUTREPIA as the first DPI treprostinil available for PAH and PH-ILD and 4) potential safety concerns with sotatercept including epistaxis and telangiectasias as evidenced by results from the Ph2 PULSAR and Ph3 STELLAR trials and a potential risk of GI bleeding according to a recently published case report in Annals of Internal Medicine (see HERE). With a padded balance sheet heading into the new year, we see focus shifting to advancing the orphan lung programs with the initiation of a Ph2/3 trial for MNKD-101 (clofazimine)/NTM lung disease in Q2:24 and the initiation of a Ph1 healthy volunteer trial for MNKD-201 (nintedanib) in H1:24.
|
|
|
Post by prcgorman2 on Jan 19, 2024 12:27:21 GMT -5
Reiterating a price target of 3x share price in 12 months? Hard to believe, but if their prediction should come true, there will be no complaints (from longs).
|
|
|
Post by Chris-C on Jan 19, 2024 18:01:36 GMT -5
Reiterating a price target of 3x share price in 12 months? Hard to believe, but if their prediction should come true, there will be no complaints (from longs). I’ll confirm that Prcgorman- no complaints here! Might just back up the SUV and get a few more shares at these bargain prices!😊🚙💰
|
|
|
Post by prcgorman2 on Jan 20, 2024 9:05:51 GMT -5
Reiterating a price target of 3x share price in 12 months? Hard to believe, but if their prediction should come true, there will be no complaints (from longs). I’ll confirm that Prcgorman- no complaints here! Might just back up the SUV and get a few more shares at these bargain prices!😊🚙💰 Adding has been weighing on my mind too. Not been convenient for the last couple of weeks, but still thinking about it.
|
|
|
Post by BD on Feb 15, 2024 16:22:36 GMT -5
Reminder: Seeking Alpha is not an "analyst". I moved the SA links over to the appropriate forum.
|
|
|
Post by radgray68 on Feb 16, 2024 14:06:37 GMT -5
I’m thinking starting the trials and ex-U.S. expansion will do something for the stock. What? I can’t guess but we’ll all think it’s slow and not enough. However, analysts on the street LOVE the terms Fast Track and Orphan if the designation is granted to a new product. Those are the moves I think we’ll ALL enjoy. IMHO
|
|
|
Post by caesar on Feb 16, 2024 17:01:43 GMT -5
FYI - As of February 9th, CFRA released a Quantitative Research Report recommending that MNKD is a STRONG BUY...
Model Ranking Commentary 1) MNKD's STRONG BUY recommendation is based on its score from CFRA's quantitative model for the United States. 2) Growth and Valuation model sub-categories are the two largest drivers of MNKD's STRONG BUY recommendation. 3) Growth includes factors that measure EPS growth and stability and cash flow growth and stability. 4) Valuation includes factors such as price to earnings, price to EBITDA, and price to cash flow. 5) MNKD's overall score ranked in the 10th percentile of all stocks in the model universe (1 = best and 100 = worst).
===============================================================
CFRA is a global leader in financial intelligence solutions and insights.
Our experienced team of experts delivers timely and actionable analysis across global markets and multiple research disciplines, ensuring you always have our most up-to-date views, analysis, and data at your fingertips so you can make smarter and faster decisions.
Founded as the Center for Financial Research and Analysis in 1994, today our company is simply known as CFRA. Our proprietary approach blends a unique mix of fundamental equity, forensic accounting, fund, public policy and technical research with data, analytics and next-gen technology to arm clients with the financial intelligence required to meet their business and investing goals.
We are fiercely independent, we are client obsessed, and our mission is simply to be the most trusted global source of independent financial intelligence and innovation.
|
|
|
Post by uvula on Feb 28, 2024 10:49:58 GMT -5
Canter Fitzgerald buy rating. $6.50 target.
|
|
|
Post by mytakeonit on Feb 28, 2024 13:10:37 GMT -5
MTOI buy rating ... is like hitting a fast moving target at $10 headed to $100 in a flash !!!
So ... buy all the not so cheap shares you can !!!
|
|
|
Post by cretin11 on Feb 28, 2024 14:25:46 GMT -5
MTOI buy rating ... is like hitting a fast moving target at $10 headed to $100 in a flash !!! So ... buy all the not so cheap shares you can !!! LOL I’ve missed this, welcome back! 🤣
|
|
|
Post by runner on Feb 28, 2024 14:29:46 GMT -5
My mantra for the next 90 minutes is: “Close over Four, Close over Four”
Namaste 🙏
|
|
|
Post by mytakeonit on Feb 28, 2024 14:43:01 GMT -5
I'm amazed at how people will release shares so cheap when the news is so GREAT ... the shorts are escaping !!!
But, that's mytakeonit
|
|
|
Post by runner on Feb 28, 2024 16:05:06 GMT -5
My mantra didn’t matter much!
|
|